GlassScriptPhysician profile
Nadia Khan
NPI 1336897644
$8,947.07
in general payments reported to CMS, 2019-2025
24 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,144 · 2023: $3,249 · 2024: $1,864 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,803.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,252.41 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Abbvie INC. | $1,081.00 | 2022-2025 | |
| Alkermes, INC. | $885.46 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $680.81 | 2022-2025 | Rexulti |
| Corium, LLC | $592.72 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $524.98 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $500.06 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $380.01 | 2022-2024 | Caplyta |
| Tris Pharma INC | $372.19 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $348.51 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neos Therapeutics, LP | $304.07 | 2022-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $277.24 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $276.68 | 2023-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $254.07 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $236.20 | 2022-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $220.48 | 2022-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $210.88 | 2022-2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $183.30 | 2022-2025 | Fanapt |
| Noven Therapeutics, LLC | $153.01 | 2023-2025 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $103.68 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $36.67 | 2022 | |
| Biogen, INC. | $27.15 | 2022 | |
| Owp Pharmaceuticals, INC. | $25.55 | 2022 | |
| Avion Pharmaceuticals | $19.94 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.